DM002

PreclinicalSmall molecule

XXadcera Biopharmaceutical (Suzhou) Co., Ltd.

DM002 is one of 13 small molecule programs targeting Ovarian Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian NeoplasmsRecruiting

Ovarian NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Ovarian Neoplasms

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

3 2

Gemzar

Johnson & Johnson

Phase 3

3 3

Keytruda

Merck & Co.

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

5 5

Paraplatin

AAvyxa

Phase 3

2 6

Hycamtin

MMeitheal

Phase 3

2 7

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

3 8

Rescue Medications

Merck & Co.

Phase 3

1 9

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 10

Mocertatug Rezetecan

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Ovarian Neoplasms

NCT06751329

Clinical

Trials by Indication[1]

Ovarian Neoplasms1 trial

A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

Recruiting·XXadcera Biopharmaceutical (Suzhou) Co., Ltd.·Preclinical·NCT06751329·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DM002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DM002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DM002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xadcera Biopharmaceutical (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: XXadcera Biopharmaceutical (Suzhou) Co., Ltd.

DM002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ovarian Neoplasms1 trial

References

Drug Info

Quick Facts

Related News